Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

fludarabine IV

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA synthesis inhibitor

Related drugs:

‹

captisol-enabled melphalan (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

cytarabine/daunorubicin liposomal formulation (19)

clofarabine (16)

carmustine (14)

temozolomide gel (7)

hydroxyurea (3)

mercaptopurine (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine-releasing intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

›

No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + fludarabine IV Sensitive: A2 - Guideline cytarabine + fludarabine IV Sensitive : A2	cytarabine + fludarabine IV Sensitive: A2 - Guideline cytarabine + fludarabine IV Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride + fludarabine IV Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + fludarabine IV Sensitive : A2	cytarabine + idarubicin hydrochloride + fludarabine IV Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + fludarabine IV Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	fludarabine IV + treosulfan Sensitive: B - Late Trials fludarabine IV + treosulfan Sensitive : B	fludarabine IV + treosulfan Sensitive: B - Late Trials fludarabine IV + treosulfan Sensitive : B
Chr del(8p)	Chronic Lymphocytic Leukemia	Chr del(8p)	Chronic Lymphocytic Leukemia	fludarabine IV Resistant: C3 – Early Trials fludarabine IV Resistant : C3	fludarabine IV Resistant: C3 – Early Trials fludarabine IV Resistant : C3
IGH mutation + Chr del(8p)	Chronic Lymphocytic Leukemia	IGH mutation + Chr del(8p)	Chronic Lymphocytic Leukemia	fludarabine IV Resistant: C3 – Early Trials fludarabine IV Resistant : C3	fludarabine IV Resistant: C3 – Early Trials fludarabine IV Resistant : C3
SAMHD1 mutation	Mantle Cell Lymphoma	SAMHD1 mutation	Mantle Cell Lymphoma	fludarabine IV Resistant: D – Preclinical fludarabine IV Resistant : D	fludarabine IV Resistant: D – Preclinical fludarabine IV Resistant : D